NU's Post-Earnings Plunge Highlights Cost Pressures Amid Strong Growth

What happened

NU stock slid 14% post-earnings despite reporting 45% revenue growth and rising profits, as investors focused on escalating near-term costs. The DeepValue report reveals a sharp spike in marketing spend to $94.2 million in Q4'25, up from $24.8 million a year earlier, raising red flags about operating leverage. This increase is tied to NU's aggressive $4.2 billion investment plan for Mexico through 2030, which risks pressuring efficiency if not matched by higher average revenue per active customer (ARPAC). Management's own warning that 2026 investments could weigh on efficiency validates the market's skepticism and aligns with the report's WAIT rating. Thus, the selloff reflects a critical reassessment of NU's ability to sustain profitability while funding long-term expansion.

Implication

The post-earnings dip signals that the market prioritizes expense management over top-line growth, reinforcing the need for a cautious investment approach. Key near-term catalysts include monitoring ARPAC trends and efficiency ratios to assess if marketing spend remains elevated without offsetting monetization. If costs persist at high levels, it could break the compounding thesis, as highlighted in the report's thesis breakers, potentially driving the stock toward the bear case value of $9.50. Additionally, regulatory headwinds in Brazil and Mexico's bank launch progress are critical for long-term valuation, requiring close scrutiny of upcoming disclosures. Therefore, maintaining a WAIT stance with entry points around $12.50 is prudent until these uncertainties resolve, protecting against downside from sustained reinvestment.

Thesis delta

The earnings reaction underscores the market's sensitivity to cost pressures, reinforcing the existing WAIT thesis that NU's valuation depends on balancing reinvestment with profitability. No material shift is needed, but it highlights the urgency of monitoring Q1-Q2 2026 reports for signs of marketing normalization and ARPAC improvement. Investors should remain vigilant, as failure to demonstrate operating leverage could quickly erode confidence and validate downside risks.